eXoZymes, Inc.
NASDAQ:EXOZBiotechnology
+$1.06 today
- Market cap
- $51.42M
- Beta
- 2.66
- P/E (TTM)
- -6.5
- EPS (TTM)
- -$1.14
Volume 0.01M
Average 0.01M
Returns on capital
eXoZymes, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-269.6%
avg 0.4%
ROIC
-203.1%
avg -101.4%
ROA
-153.4%
avg -71.8%
Analysis
ROA is currently the strongest return metric at -153.4% versus its period average of -71.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Michael Heltzen | President & Chief Executive Officer | USD 608.33K | 45 | 14.45K | 0.17% |
Damien A. Perriman | Chief Commercial Officer | USD 310.76K | 49 | — | — |
Tyler Korman | Co-Founder & Chief Scientific Officer | USD 260.42K | 47 | — | — |
Fouad Nawaz | Vice President of Finance | USD 258.33K | 40 | 45.00K | 0.53% |
Paul Opgenorth | Co-Founder & Vice President of Development | USD 257.29K | 43 | — | — |
James U. Bowie | Founder & Independent Director | — | 64 | — | — |
Lasse H. Gorlitz | Vice President of Communications | — | — | — | — |
Michael Burns | Executive Vice President of Energy Transition | — | — | — | — |
Amy Lunzer | Chief of Staff | — | — | — | — |
Compensation is shown in the reported currency; data updated Sep 19, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 14, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
5
$6,405.17
Sells
2
$15,424.20
Net Transaction Value
−$9,019.03
Net selling
Most Active
Heltzen Michael
5 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Aug 26, 26Aug 26, 2026 | Heltzen Michael Direct | Buy | $30.3$30.32 |
| Aug 26, 26Aug 26, 2026 | Heltzen Michael Direct | Buy | $1.8K$1,844.85 |
| Aug 26, 26Aug 26, 2026 | Heltzen Michael Direct | Buy | $1.9K$1,900.00 |
| Aug 25, 26Aug 25, 2026 | Heltzen Michael Direct | Buy | $1.9K$1,880.00 |
| Aug 25, 26Aug 25, 2026 | Heltzen Michael Direct | Buy | $750$750.00 |
| Apr 9, 26Apr 9, 2026 | Korman Tyler Paz Direct | Sell | $7.9K$7,893.75 |
| Apr 8, 26Apr 8, 2026 | Korman Tyler Paz Direct | Sell | $7.5K$7,530.45 |
Summary
Insiders reported 5 buys worth $6,405.17 and 2 sells worth $15,424.20 over the last 12 months. That adds up to net selling of $9,019.03. Heltzen Michael was the most active insider with 5 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Competitors
Who does eXoZymes, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about EXOZ's management, answered from reported figures.
Who manages EXOZ?
eXoZymes, Inc. (EXOZ) lists 9 active executives. The top listed executive is Paul Opgenorth, Co-Founder & Vice President of Development.
Are EXOZ insiders buying or selling?
Recent insider activity shows net buying of $4.98M.
Continue the stock analysis
Jump to another research area for this company.